The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.
Neutropenia refers to reduced neutrophil count in the blood. Normal individuals have a neutrophil count in the blood ranging between 1,500 and 8,000 cells/cubic meter. When neutrophil count falls below the 1,500 cells/mm3 threshold, a patient is classified as neutropenic. Generally, neutrophils drop below normal level within after 7-12 days of cancer chemotherapy.
The demand for neutropenia therapy is projected to experience substantial growth in the future, owing to growth in incidences of cancer cases. Increase in R&D activities by key companies to establish new neutropenia therapies are also anticipated to fuel the demand during the forecast period. However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period. In addition, paradigm transition from branded drugs to low-cost biosimilars is projected to provide industry players with remunerative incentives.
Depending on treatment, the market is categorized into colony-stimulating factors, antibiotics, antifungals, and antivirals. The colony-stimulating factors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Rise in incidences of cancer cases and further increase in number of patients undergoing chemotherapy around the globe drives the growth of this treatment segment.
On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
North America accounted for the largest share in the global neutropenia treatment market. Further, Asia-Pacific is expected to witness highest growth rate for the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period. As, Europe is considered as the advanced biosimilar market as compared to non-European countries, high cost of the treatment of neutropenia is expected to restrict the growth of the market during the forecast period.
The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
BY Treatment
BY Distribution Channel
By Region
KEY MARKET PLAYERS
Neutropenia refers to reduced neutrophil count in the blood. Normal individuals have a neutrophil count in the blood ranging between 1,500 and 8,000 cells/cubic meter. When neutrophil count falls below the 1,500 cells/mm3 threshold, a patient is classified as neutropenic. Generally, neutrophils drop below normal level within after 7-12 days of cancer chemotherapy.
The demand for neutropenia therapy is projected to experience substantial growth in the future, owing to growth in incidences of cancer cases. Increase in R&D activities by key companies to establish new neutropenia therapies are also anticipated to fuel the demand during the forecast period. However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period. In addition, paradigm transition from branded drugs to low-cost biosimilars is projected to provide industry players with remunerative incentives.
Depending on treatment, the market is categorized into colony-stimulating factors, antibiotics, antifungals, and antivirals. The colony-stimulating factors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Rise in incidences of cancer cases and further increase in number of patients undergoing chemotherapy around the globe drives the growth of this treatment segment.
On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
North America accounted for the largest share in the global neutropenia treatment market. Further, Asia-Pacific is expected to witness highest growth rate for the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period. As, Europe is considered as the advanced biosimilar market as compared to non-European countries, high cost of the treatment of neutropenia is expected to restrict the growth of the market during the forecast period.
The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current neutropenia treatment trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The market forecast is studied from 2020 to 2027.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
BY Treatment
- Colony-stimulating factors,
- Antibiotics
- Antifungals
- Antivirals
BY Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
KEY MARKET PLAYERS
- Amgen
- BeyondSpring
- Kyowa Kirin
- Cellerant Therapeutics
- Mylan N.V.
- Novartis AG
- Partner Therapeutics
- Pfizer
- Spectrum Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Coherus Biosciences
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Global Neutropenia Treatment Market, by Treatment
Chapter 5: Global Neutropenia Treatment Market, by Distribution Channel
Chapter 6: Global Neutropenia Treatment Market, by Region
Chapter 7: Company Profiles
Executive Summary
According to the report titled, 'Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals and Antivirals), by Distribution Channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Opportunity Analysis and Industry Forecast, 2019-2027' the global neutropenia market size is expected to reach $19,303.1 million by 2027, registering a CAGR of 5.4% from 2020 to 2027, in terms of value.Neutropenia is a disease in which the amount of white blood cells (neutrophils) in the blood supply is decreased, reducing the capacity of the body to combat infections. Neutropenia is defined as an absolute count of neutrophils (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
Neutrophils play an important role in immune defenses because they ingest, kill, and digest invading microbes such as fungi and bacteria. Neutropenia is a disease associated with low white blood cell count.. These white blood cells are called neutrophils. Further, some of the major causes for neutropenia are cancer chemotherapy, radiation therapy stem cell, or bone marrow transplants. The treatment for neutropenia is dependent on the underlying cause, severity, and associated infections related to overall health of patients.
The neutropenia market is expected to register a substantial growth in the future, owing to rise in incidences of cancer cases. In addition, an increase in R&D efforts by companies to develop novel therapies for treatment of neutropenia is expected to boost market growth during the forecast period.
However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the neutropenia treatment market growth during the forecast period. On the contrary, fundamental shift from branded drugs to low cost biosimilars is expected to provide remunerative opportunities for the market players.
The neutropenia cancer market is segmented on the basis of treatment and distribution channel. By treatment, it is categorized into colony-stimulating factor, antibiotics, and antifungals. Colony-stimulating factors are secreted glycoproteins.. These bind to receptor proteins on the surface of hematopoietic stem cells. The colony-stimulating factors are of two types, namely, granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
On the basis of distribution channel, it is divided into hospitals pharmacies, retail pharmacies, and online pharmacies. Neutropenia treatment drugs are marketed by various sales channel such as pharmacies, within the hospitals.. These medications are also offered by online providers through registered websites, which offer the ease of ordering medicines over the internet. The retail pharmacies segment is expected to dominate the global neutropenia market, owing to adequate supply of products and easy availability and accessibility of retail pharmacies. Online pharmacies are projected to generate significant revenue in the global neutropenia treatment market during the forecast period.
The global neutropenia treatment market is segmented on the basis of region into North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
North America accounted for the largest the global neutropenia treatment market share. The neutropenia treatment market witnessed a vast growth in North America and is expected to dominate the market in the coming years. This is attributed to the increase in incidences of leukemia in the region. According to the International Agency for Research on Cancer, in 2018, 169,270 people are living with leukemia for five years and 58,876 new leukemia cases were diagnosed in North America. In addition, major key players of the market operate in North America. Further, the demand for neutropenia treatment in North America is dominated by the US. The dominance of the region is due to a rise in demand for medicinal needs for febrile neutropenia and introduction of new legislation for promotion and production of biosimilars.
Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Asia possesses high potential for the growth of neutropenia treatment market, owing to leukemia cases and number of patients undergoing first-line chemotherapy treatment.
The key players operating in the neutropenia market include Amgen, BeyondSpring, Kyowa Kirin, Cellerant. Therapeutics, Mylan N.V., Novartis AG, Partner. Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players neutropenia market (not profiled in the report) include Myelo. Therapeutics, Enzychem Lifesciences Corporation Samsung Medical Center and among others.
Key Findings of the Study:
Based on treatment, the colony-stimulating factors segment accounted for a $10, 211.5 in the global neutropenia market in 2019.
Based on distribution channel, the hospital pharmacies segment account for the largest share and the online pharmacies segment is anticipated to grow with the highest CAGR of 6.0% throughout the forecast period.
Companies Mentioned
- Amgen
- BeyondSpring
- Kyowa Kirin
- Cellerant Therapeutics
- Mylan N.V.
- Novartis AG
- Partner Therapeutics
- Pfizer
- Spectrum Pharmaceuticals
- Teva Pharmaceutical Industries Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
